• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Tufts University

Headquarters: Medford, MA, United States
Year Founded: 1852
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Apr 11, 2025
Discovery & Translation

Base editor efficiency boom. China leading charge?

Recently published studies reveal advances in precision and performance, driven largely by labs in China
BioCentury | Jan 4, 2025
Market Access

Accelerated approval speed bump will limit access, disincentivize orphan drug development

Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months
BioCentury | Dec 6, 2024
Product Development

KCC2 activation nears inflection point

Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders
BioCentury | Oct 8, 2024
Management Tracks

Veteran investor Oleg Nodelman joins Galapagos board

Plus: New CEOs at QuantX, Oak Hill, and updates from Every Cure, Mosaic, Anixa and more 
BioCentury | Jul 5, 2024
Product Development

LNP innovation: tissue specificity, aided by AI

How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
BioCentury | Jun 7, 2023
Finance

June 7 Quick Takes: Radiopharma play ITM raises €255M

Plus: LNP company Hopewell emerges with $25M seed round and updates from Mozart, GSK, FibroGen and Deerfield
BioCentury | Feb 15, 2023
Politics, Policy & Law

CMS proposes payment models for accelerated approval, gene & cell therapies

Models will not be implemented for years, industry will have chance to comment
BioCentury | Jun 8, 2022
Regulation

FDA panel backs Novavax vaccine, citing need for another technology

Advisory committee says another non-mRNA vaccine is needed, expresses desire to encourage more COVID-19 vaccine development
BioCentury | May 12, 2022
Politics, Policy & Law

Biopharma companies facing tough decisions in Russia

Pharmaceutical companies balancing calls to disengage vs. duties to patients
Items per page:
1 - 10 of 130